LOGO
LOGO

Clinical Trial Calendar

Results Date
Company Name
Ticker
Event
Indication
Outcome
Q2 2026
Oculis Holding AG
OCS
Top-line data readout from Phase 3 trial of OCS-01 (DIAMOND)
Diabetic macular edema (DME)
Phase 3 trials of OCS-01 eye drops in patients with diabetic macular edema failed to meet primary endpoint and secondary end points, according to the company. The data reported on 30th May 2026.
Q2 2026
Edgewise Therapeutics, Inc.
EWTX
12-week (Part D) data from Phase 2 trial of EDG-7500 (CIRRUS-HCM)
Obstructive and non-obstructive Hypertrophic Cardiomyopathy (HCM)
Q2 2026
Virax Biolabs Group Limited
VRAX
Initial data from the longitudinal assessment of the ViraxImmune FluoroSpot T cell assay's performance in detecting T cell dysfunction
Post-acute infection syndrome patients
Q2 2026
Oruka Therapeutics, Inc.
ORKA
Data from Phase 2a proof-of-concept study of ORKA-001
Moderate-to-severe psoriasis
Q2 2026
ProMIS Neurosciences, Inc.
PMN
Interim data from Phase 1b trial of PMN310 (PRECISE-AD)
Alzheimer’s Disease
Q2 2026
Apogee Therapeutics, Inc.
APGE
16-week Part B data from Phase 2 trial of APF777 (APEX)
Atopic dermatitis
Positive 16-Week Part B results reported from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis on 27th May 2026.
Q2 2026
Neumora Therapeutics, Inc.
NMRA
Topline Phase 3 data of navacaprant (KOSTAL-2)
Major Depressive Disorder (MDD)

Q2 2026
Black Diamond Therapeutics
BDTX
Updated data from Phase 2 trial of BDTX-1535
Recurrent epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC)
Q2 2026
ABIVAX SA
ABVX.PA, ABVX
Topline phase 3 44-week maintenance data of Obefazimod (ABTECT)
Moderately to severely active ulcerative colitis
Q2 2026
Neumora Therapeutics, Inc.
NMRA
Topline Phase III data of navacaprant (KOASTAL-2)
Major Depressive Disorder (MDD)
Q2 2026
Immunic, Inc
IMUX
Topline Phase 2 data of Vidofludimus calcium (ENSURE)
Multiple Sclerosis (MS)
Q2 2026
Mural Oncology plc
MURA
Final overall survival data from phase 3 trial of nemvaleukin in combination with pembrolizumab (ARTISTRY-7)
Platinum-resistant ovarian cancer
The ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with Merck’s pembrolizumab in patients with platinum-resistant ovarian cancer (PROC) will not continue to final analysis and the company will cease development of nemvaleukin for PROC, according to the company. The data reported on Mar. 25, 2025.
Q2 2026
Cullinan Therapeutics, Inc.
CGEM
Initial data from Phase 1 study of CLN-978
Moderate to severe systemic lupus erythematosus (SLE)
Q2 2026
Coherus Oncology, Inc.
CHRS
Initial data from Phase 1b dose optimization study of CHS-114 in combination with toripalimab
Second-line gastric cancer
Q2 2026
Astria Therapeutics Inc
ATXS
Proof-of-concept results from Phase 1a trial of STAR-0310
Atopic dermatitis
Q2 2026
Immix Biopharma, Inc
IMMX
Final topline clinical data readout from Phase 2 trial of NXC-201 (NEXICART-2)
Relapsed/refractory AL Amyloidosis
Q2 2026
Spyre Therapeutics, Inc.
SYRE
Part A topline data from Phase 2 trial of SPY001 (SKYLINE)
Moderately-to-severely active ulcerative colitis
Positive 12-week induction data reported from Part A of the Phase 2 SKYLINE trial of SPY001 for the treatment of moderate-to-severely active ulcerative colitis on 13th April 2026.
Q2 2026
Rapport Therapeutics, Inc.
RAPP
8-week follow-up results from Phase 2a trial of RAP-219
Focal onset seizures (FOS)
Q2 2026
Taysha Gene Therapies, Inc.
TSHA
Longer-term safety and efficacy data from Part A of Phase 1/2 trial of TSHA-102 (REVEAL)
Rett syndrome
Q2 2026
Biomarin Pharmaceutical Inc.
BMRN
Topline data from Phase 3 trial of BMN 401 in Children ages 1-to-12 year-old
ENPP1 deficiency
Q2 2026
Biomarin Pharmaceutical Inc.
BMRN
Topline data from Phase 3 trial of VOXZOGO
Hypochondroplasia
Q2 2026
Vera Therapeutics, Inc.
VERA
Initial results from Phase 2 trial of atacicept (PIONEER)
Expanded IgAN populations and other autoimmune kidney diseases
Q2 2026
Shattuck Labs, Inc
STTK
Data from Phase 1 trial of SL-325
Inflammatory Bowel Disease
Q2 2026
TScan Therapeutics, Inc.
TCRX
Early data from Cohort C of Phase 1 heme trial of TSC-101 (ALLOHA)
Acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or myelodysplastic syndrome (MDS) in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
Q2 2026
Absci Corp
ABSI
Preliminary safety, tolerability, and PK data from Phase 1/2a trial of AI-designed antibody ABS-201 (HEADLINE)
Androgenetic Alopecia
Buy this Content
Editors Pick
gsk 09062026 lt

Nuvalent Stock Climbs 39% On $10.6 Bln Takeover Deal With GSK

June 09, 2026 08:05 ET
chatgpt 09062026 lt

OpenAI Joins IPO Race With Confidential S-1 Filing

June 09, 2026 05:10 ET
tateandlylev2 08062026 lt

Tate & Lyle Stock Up On $3.6 Bln Cash Deal To Be Bought By Ingredion

June 08, 2026 07:11 ET
spacexx 26032026 lt

SpaceX Aims To Raise Around $75 Bln In IPO, Musk May Become World's First Trillionaire

June 04, 2026 07:12 ET
Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap